| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dengue | 56 | 2018 | 98 | 4.570 |
Why?
|
| Dengue Virus | 46 | 2018 | 101 | 3.380 |
Why?
|
| Severe Dengue | 22 | 2016 | 24 | 1.890 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2018 | 679 | 1.460 |
Why?
|
| Antibodies, Viral | 17 | 2015 | 329 | 1.010 |
Why?
|
| West Nile virus | 5 | 2012 | 6 | 0.890 |
Why?
|
| Antigens, Viral | 7 | 2011 | 130 | 0.830 |
Why?
|
| Thailand | 34 | 2018 | 91 | 0.740 |
Why?
|
| Flavivirus Infections | 2 | 2010 | 4 | 0.640 |
Why?
|
| Child | 55 | 2018 | 4651 | 0.630 |
Why?
|
| Viremia | 10 | 2012 | 46 | 0.600 |
Why?
|
| Virus Replication | 6 | 2016 | 323 | 0.510 |
Why?
|
| Epitopes, T-Lymphocyte | 8 | 2014 | 186 | 0.500 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2011 | 241 | 0.480 |
Why?
|
| Child, Preschool | 32 | 2018 | 2089 | 0.470 |
Why?
|
| Severity of Illness Index | 13 | 2015 | 1569 | 0.450 |
Why?
|
| Viral Nonstructural Proteins | 8 | 2014 | 99 | 0.440 |
Why?
|
| Plasma | 2 | 2014 | 39 | 0.430 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2014 | 44 | 0.410 |
Why?
|
| Infant | 24 | 2018 | 1718 | 0.390 |
Why?
|
| Oxygen | 1 | 2014 | 323 | 0.370 |
Why?
|
| Pleural Effusion | 3 | 2014 | 40 | 0.370 |
Why?
|
| Adolescent | 37 | 2018 | 6367 | 0.360 |
Why?
|
| Immunologic Memory | 3 | 2011 | 284 | 0.360 |
Why?
|
| Interferon-gamma | 10 | 2011 | 576 | 0.350 |
Why?
|
| Viral Vaccines | 7 | 2010 | 56 | 0.350 |
Why?
|
| West Nile Virus Vaccines | 1 | 2011 | 1 | 0.340 |
Why?
|
| Smallpox | 1 | 2010 | 6 | 0.330 |
Why?
|
| Smallpox Vaccine | 1 | 2010 | 11 | 0.330 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2010 | 2 | 0.320 |
Why?
|
| Antigens, CD | 5 | 2014 | 344 | 0.300 |
Why?
|
| Viral Load | 6 | 2012 | 230 | 0.300 |
Why?
|
| Humans | 81 | 2018 | 65831 | 0.290 |
Why?
|
| RNA, Viral | 7 | 2013 | 267 | 0.290 |
Why?
|
| T-Lymphocytes | 8 | 2008 | 1012 | 0.280 |
Why?
|
| West Nile Fever | 4 | 2012 | 4 | 0.280 |
Why?
|
| Vaccines, Attenuated | 4 | 2011 | 35 | 0.280 |
Why?
|
| Cross Reactions | 9 | 2013 | 140 | 0.270 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 29 | 0.250 |
Why?
|
| Female | 42 | 2018 | 34420 | 0.230 |
Why?
|
| Zika Virus | 2 | 2016 | 38 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1998 | 138 | 0.230 |
Why?
|
| Prospective Studies | 21 | 2013 | 3339 | 0.220 |
Why?
|
| Aging | 1 | 2010 | 784 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2018 | 642 | 0.210 |
Why?
|
| Neutralization Tests | 6 | 2010 | 126 | 0.210 |
Why?
|
| Male | 42 | 2018 | 31403 | 0.210 |
Why?
|
| Viral Envelope Proteins | 4 | 2011 | 102 | 0.210 |
Why?
|
| Serotyping | 11 | 2011 | 52 | 0.210 |
Why?
|
| B-Lymphocytes | 5 | 2016 | 565 | 0.210 |
Why?
|
| Lymphocyte Activation | 8 | 2014 | 755 | 0.200 |
Why?
|
| Vaccinia virus | 3 | 2010 | 69 | 0.200 |
Why?
|
| AIDS Vaccines | 3 | 2008 | 73 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2007 | 220 | 0.200 |
Why?
|
| HLA-B Antigens | 3 | 2014 | 13 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2012 | 449 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 6 | 2012 | 3506 | 0.170 |
Why?
|
| Cohort Studies | 10 | 2015 | 2651 | 0.170 |
Why?
|
| Acute Disease | 11 | 2018 | 665 | 0.170 |
Why?
|
| Fever | 6 | 2014 | 67 | 0.170 |
Why?
|
| Amino Acid Sequence | 5 | 2010 | 1590 | 0.160 |
Why?
|
| Radiography, Thoracic | 2 | 2014 | 117 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2011 | 605 | 0.160 |
Why?
|
| Immunodominant Epitopes | 2 | 2010 | 59 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2018 | 129 | 0.160 |
Why?
|
| Interleukin-12 | 2 | 1999 | 127 | 0.160 |
Why?
|
| Immunization | 2 | 2010 | 135 | 0.150 |
Why?
|
| Interleukin-10 | 2 | 2002 | 165 | 0.150 |
Why?
|
| Body Fluids | 2 | 2014 | 21 | 0.150 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1999 | 111 | 0.150 |
Why?
|
| Vaccines, DNA | 3 | 2008 | 98 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 279 | 0.140 |
Why?
|
| Public Service Announcements as Topic | 1 | 2018 | 3 | 0.140 |
Why?
|
| Capillary Permeability | 2 | 2010 | 17 | 0.140 |
Why?
|
| Aedes | 2 | 2012 | 14 | 0.140 |
Why?
|
| Mice | 9 | 2016 | 11185 | 0.140 |
Why?
|
| Viral Plaque Assay | 2 | 2010 | 15 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2012 | 248 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2005 | 542 | 0.140 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 112 | 0.140 |
Why?
|
| Immunoglobulin G | 7 | 2012 | 472 | 0.140 |
Why?
|
| Fear | 1 | 2018 | 71 | 0.130 |
Why?
|
| Phenotype | 3 | 2018 | 1236 | 0.130 |
Why?
|
| Human Experimentation | 4 | 2011 | 32 | 0.130 |
Why?
|
| Animals | 17 | 2016 | 21492 | 0.130 |
Why?
|
| Cytokines | 4 | 2010 | 965 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2018 | 163 | 0.130 |
Why?
|
| CD4 Antigens | 2 | 1997 | 149 | 0.130 |
Why?
|
| Population Surveillance | 3 | 2015 | 210 | 0.130 |
Why?
|
| HIV Antibodies | 2 | 2008 | 146 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 312 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 196 | 0.120 |
Why?
|
| Serogroup | 1 | 2016 | 35 | 0.120 |
Why?
|
| Photoplethysmography | 1 | 2016 | 38 | 0.120 |
Why?
|
| Recurrence | 3 | 2008 | 665 | 0.120 |
Why?
|
| Immunoassay | 1 | 2016 | 71 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2016 | 46 | 0.120 |
Why?
|
| Antigens, Differentiation | 1 | 2016 | 144 | 0.120 |
Why?
|
| Immunity, Cellular | 3 | 2010 | 170 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 7 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 167 | 0.110 |
Why?
|
| Genes, MHC Class I | 1 | 2015 | 26 | 0.110 |
Why?
|
| Cluster Analysis | 5 | 2014 | 267 | 0.110 |
Why?
|
| HLA Antigens | 2 | 2009 | 62 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 7 | 2012 | 514 | 0.100 |
Why?
|
| Oximetry | 1 | 2014 | 53 | 0.100 |
Why?
|
| Adoptive Transfer | 2 | 2012 | 145 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 1980 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 220 | 0.100 |
Why?
|
| Chemokine CCL4 | 2 | 2011 | 14 | 0.100 |
Why?
|
| Genetic Variation | 2 | 2006 | 395 | 0.100 |
Why?
|
| Platelet Count | 2 | 2010 | 27 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2005 | 169 | 0.100 |
Why?
|
| Genomics | 1 | 2016 | 387 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 223 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 737 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 12 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 446 | 0.090 |
Why?
|
| Lymphocytes | 1 | 1993 | 210 | 0.090 |
Why?
|
| Epitopes | 2 | 2010 | 291 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 1 | 2012 | 20 | 0.090 |
Why?
|
| Peptide Fragments | 3 | 2010 | 419 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2014 | 1029 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2010 | 365 | 0.090 |
Why?
|
| Lymphotoxin-alpha | 2 | 2009 | 7 | 0.090 |
Why?
|
| Immunization, Secondary | 2 | 2008 | 52 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2010 | 1172 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2010 | 25 | 0.080 |
Why?
|
| Placebos | 1 | 2011 | 73 | 0.080 |
Why?
|
| HLA-A Antigens | 3 | 2010 | 8 | 0.080 |
Why?
|
| Coinfection | 1 | 2011 | 59 | 0.080 |
Why?
|
| Biomarkers | 3 | 2010 | 1502 | 0.080 |
Why?
|
| Flavivirus | 1 | 2010 | 8 | 0.080 |
Why?
|
| Vero Cells | 1 | 2010 | 81 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2010 | 42 | 0.080 |
Why?
|
| Lymphokines | 1 | 2010 | 67 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2016 | 926 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2010 | 13 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2010 | 173 | 0.080 |
Why?
|
| Immunity | 1 | 2011 | 107 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2010 | 135 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 1291 | 0.080 |
Why?
|
| Spleen | 1 | 2010 | 476 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2010 | 95 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2011 | 205 | 0.070 |
Why?
|
| Paramyxoviridae Infections | 1 | 2008 | 8 | 0.070 |
Why?
|
| Metapneumovirus | 1 | 2008 | 7 | 0.070 |
Why?
|
| Leptospirosis | 1 | 2007 | 2 | 0.070 |
Why?
|
| Time Factors | 5 | 2015 | 3777 | 0.070 |
Why?
|
| Vaccination | 1 | 2011 | 388 | 0.070 |
Why?
|
| HIV-1 | 2 | 2008 | 710 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 2007 | 4 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2007 | 50 | 0.060 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2005 | 27 | 0.060 |
Why?
|
| Disease Progression | 2 | 2010 | 1229 | 0.060 |
Why?
|
| Ascites | 1 | 2007 | 22 | 0.060 |
Why?
|
| Superinfection | 1 | 2007 | 12 | 0.060 |
Why?
|
| Gallbladder | 1 | 2007 | 40 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 22 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2008 | 130 | 0.060 |
Why?
|
| Schools | 3 | 2013 | 170 | 0.060 |
Why?
|
| Incidence | 5 | 2012 | 1433 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2008 | 273 | 0.060 |
Why?
|
| Cells, Cultured | 6 | 2006 | 2194 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2007 | 147 | 0.060 |
Why?
|
| Rural Population | 3 | 2013 | 225 | 0.060 |
Why?
|
| Hospitalization | 3 | 2015 | 1404 | 0.060 |
Why?
|
| Immunoglobulin M | 4 | 2012 | 116 | 0.060 |
Why?
|
| Neurons | 1 | 2012 | 935 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2007 | 169 | 0.060 |
Why?
|
| Clone Cells | 2 | 1997 | 111 | 0.060 |
Why?
|
| Lung | 1 | 2010 | 969 | 0.060 |
Why?
|
| Technology, Pharmaceutical | 1 | 2005 | 20 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 234 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2016 | 541 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2007 | 491 | 0.050 |
Why?
|
| Monocytes | 3 | 2002 | 362 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 932 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2003 | 52 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 295 | 0.050 |
Why?
|
| Logistic Models | 3 | 2015 | 1274 | 0.050 |
Why?
|
| DNA Primers | 2 | 2009 | 302 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2002 | 29 | 0.050 |
Why?
|
| Algorithms | 3 | 2016 | 1060 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2002 | 64 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 1999 | 71 | 0.050 |
Why?
|
| Body Fluid Compartments | 1 | 2002 | 3 | 0.050 |
Why?
|
| Risk Factors | 5 | 2015 | 5476 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2012 | 606 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2001 | 7 | 0.040 |
Why?
|
| Alleles | 1 | 2002 | 455 | 0.040 |
Why?
|
| Leukocyte Count | 3 | 2010 | 102 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1100 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 757 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2003 | 534 | 0.040 |
Why?
|
| World Health Organization | 2 | 2010 | 36 | 0.040 |
Why?
|
| Students | 2 | 2013 | 227 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 758 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 1999 | 194 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 1999 | 80 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1999 | 23 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2016 | 128 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 47 | 0.040 |
Why?
|
| Gene Expression | 1 | 2002 | 856 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1146 | 0.040 |
Why?
|
| Vaccines, Subunit | 2 | 2008 | 40 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1999 | 187 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2008 | 80 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 2 | 2010 | 35 | 0.030 |
Why?
|
| Interleukin-2 | 3 | 2002 | 168 | 0.030 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2016 | 11 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2011 | 9 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 35 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 2016 | 47 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 117 | 0.030 |
Why?
|
| Zika Virus Infection | 1 | 2016 | 39 | 0.030 |
Why?
|
| Virion | 1 | 2016 | 122 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 144 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2016 | 253 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 180 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 312 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 405 | 0.030 |
Why?
|
| Adult | 5 | 2008 | 17575 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 174 | 0.030 |
Why?
|
| Geography, Medical | 1 | 2014 | 5 | 0.030 |
Why?
|
| Spatial Analysis | 1 | 2014 | 12 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 664 | 0.030 |
Why?
|
| HLA-A2 Antigen | 2 | 2006 | 62 | 0.030 |
Why?
|
| Culicidae | 2 | 2008 | 14 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 537 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1993 | 63 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 506 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1993 | 19 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1993 | 52 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 1999 | 875 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1993 | 25 | 0.020 |
Why?
|
| Shock, Septic | 1 | 1994 | 89 | 0.020 |
Why?
|
| Brain | 2 | 2012 | 1672 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 647 | 0.020 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 369 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2005 | 111 | 0.020 |
Why?
|
| Hospitals | 1 | 2015 | 399 | 0.020 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2011 | 5 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2011 | 5 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 12 | 0.020 |
Why?
|
| Housing | 1 | 2012 | 74 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1638 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2002 | 413 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 137 | 0.020 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 98 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 210 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 93 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 103 | 0.020 |
Why?
|
| Asymptomatic Infections | 1 | 2011 | 29 | 0.020 |
Why?
|
| Hematocrit | 1 | 2010 | 32 | 0.020 |
Why?
|
| Nucleoside-Triphosphatase | 2 | 2002 | 43 | 0.020 |
Why?
|
| Interleukin-4 | 2 | 2002 | 147 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1117 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 344 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 56 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 110 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 80 | 0.020 |
Why?
|
| RNA Helicases | 2 | 2002 | 99 | 0.020 |
Why?
|
| Serine Endopeptidases | 2 | 2002 | 125 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2002 | 134 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 710 | 0.020 |
Why?
|
| Mosquito Control | 1 | 2008 | 8 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 85 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 518 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 484 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 330 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 223 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2008 | 19 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 869 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 199 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 105 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 282 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 77 | 0.020 |
Why?
|
| Saponins | 1 | 2008 | 26 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 178 | 0.020 |
Why?
|
| Vasculitis | 1 | 2008 | 49 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 149 | 0.020 |
Why?
|
| Middle Aged | 3 | 2011 | 18498 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 213 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 899 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2168 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2006 | 14 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1635 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 238 | 0.020 |
Why?
|
| Blood Cells | 1 | 2006 | 17 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 1438 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 170 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2007 | 86 | 0.020 |
Why?
|
| Yellow fever virus | 1 | 2006 | 6 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 193 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 11 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2006 | 48 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 1595 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2006 | 34 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 2031 | 0.010 |
Why?
|
| Flaviviridae | 1 | 2005 | 1 | 0.010 |
Why?
|
| Indonesia | 1 | 2005 | 10 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 180 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 1793 | 0.010 |
Why?
|
| Safety | 1 | 2006 | 142 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2005 | 57 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5834 | 0.010 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2005 | 6 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 47 | 0.010 |
Why?
|
| Cell Degranulation | 1 | 2005 | 23 | 0.010 |
Why?
|
| United States | 1 | 2018 | 8186 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 2005 | 63 | 0.010 |
Why?
|
| Skin | 1 | 2008 | 436 | 0.010 |
Why?
|
| Physicians | 1 | 2010 | 488 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 232 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 747 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 963 | 0.010 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2003 | 12 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 417 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2003 | 101 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 1332 | 0.010 |
Why?
|
| HLA-B51 Antigen | 1 | 2002 | 1 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2003 | 263 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 2002 | 3 | 0.010 |
Why?
|
| Japanese Encephalitis Vaccines | 1 | 2002 | 1 | 0.010 |
Why?
|
| HLA-B7 Antigen | 1 | 2002 | 2 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 124 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 108 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2002 | 40 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 2002 | 50 | 0.010 |
Why?
|
| Electric Impedance | 1 | 2002 | 38 | 0.010 |
Why?
|
| Body Height | 1 | 2002 | 66 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 165 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 33 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 46 | 0.010 |
Why?
|
| Interferon Type I | 1 | 2003 | 198 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2001 | 41 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 498 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 451 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 377 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1573 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3170 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 4882 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1999 | 15 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 14 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1999 | 32 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 1999 | 30 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1999 | 62 | 0.010 |
Why?
|
| Ethidium | 1 | 1998 | 2 | 0.010 |
Why?
|
| Cell Communication | 1 | 1999 | 135 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 180 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 52 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 6955 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1998 | 31 | 0.010 |
Why?
|
| Quality Control | 1 | 1998 | 79 | 0.010 |
Why?
|
| Virulence | 1 | 1998 | 199 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 37 | 0.010 |
Why?
|
| Insect Vectors | 1 | 1997 | 15 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 302 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 491 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1998 | 118 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1997 | 39 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 1998 | 182 | 0.010 |
Why?
|
| Phylogeny | 1 | 1998 | 399 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 2329 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 1998 | 351 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1993 | 17 | 0.010 |
Why?
|
| Syndrome | 1 | 1994 | 182 | 0.010 |
Why?
|
| Models, Biological | 1 | 1994 | 1193 | 0.000 |
Why?
|